BillionToOne (BLLN.US) debuts on Nasdaq, surging 81.57% on the first day, market value reaching nearly $4.8 billion.

Biotechnology diagnostics company BillionToOne (BLLN.US) officially landed on the Nasdaq on Thursday, with the opening stock price skyrocketing. By the close of trading, the stock had risen by 81.57%, with a market value quickly rising to nearly $4.8 billion, making it a standout new stock that went public against the backdrop of a government shutdown. Despite the limited auditing capacity of the Securities and Exchange Commission (SEC) due to the shutdown, IPO activity has picked up in recent months, driven by market enthusiasm for artificial intelligence, expectations of interest rate cuts, and support from the record highs in the US stock market. Biotechnology and high-growth companies have been particularly attractive to investors. BillionToOne's IPO price was $60, but it opened at $100 and reached a high of nearly $123.45 during trading. The company issued 4.55 million shares, raising $273 million, which is significantly higher than the original $49-55 price range. Co-founder and CEO Oguzhan Atay stated that the decision to increase the issuance size was to allow long-term investors to have more ample holding space. BillionToOne is currently based in Menlo Park, California, and focuses on developing non-invasive prenatal testing (NIPT) and tumor blood testing based on single-molecule sequencing technology. Financial data shows that in the first half of the year ending on June 30th, the company's revenue increased by 82% year-on-year, and gross profit doubled, demonstrating strong commercialization capabilities and growth momentum. The popularity of this IPO also reflects the continued interest in high-growth medical technology companies in the capital market. Many healthcare companies have gone public in the US this year, such as Caris Life Sciences (CAI.US), which went public in June and is currently trading nearly 40% higher than its IPO price, indicating institutional investors' continued high interest in the medical diagnostics sector. In the ongoing government shutdown and limited SEC approval procedures, BillionToOne's successful IPO is seen as an important signal of the recovery of the IPO market.